The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine ... nasal spray Spravato is now a mainstream prescription for treatment-resistant depression ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorized sale of an esketamine ... for Singapore, but Spravato is available at about 2,800 treatment centers worldwide ...

the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about using the ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision, this ...